Answers are grounded in this paper and cite their sources.
Cross-sectional study compares blood inflammation markers in smokers and non-smokers, highlighting implications for COPD management.
Cigarette smoking is a major driver of airway and systemic inflammation and contributes to the development and progression of chronic obstructive pulmonary disease (COPD). This study compared peripheral blood inflammatory markers and immune cell profiles in smokers with and without COPD and in non-smoking controls. In this cross-sectional study, blood samples were collected from 80 participants (n = 20/group): non-smoker controls (NS), smokers with normal lung function (NLFS), current smokers with COPD (COPD-CS), and ex-smokers with COPD (COPD-ES). Total white cell count (WCC) and leukocyte differentials (neutrophils, lymphocytes, monocytes, eosinophils) were measured using an automated haematology analyser (Sysmex XN2000). Systemic inflammatory markers were measured using C-reactive protein (CRP, Roche Cobas Pro) and erythrocyte sedimentation rate (ESR, Diesse VES-MATIC Easy). Lung function parameters (including FEV1, FVC, DLco, FEF25–75%, and SpO2) were assessed and correlated with blood markers. Compared with NS, WCC, neutrophils, and monocytes were higher in both COPD groups and in NLFS (all p < 0.05). Lymphocytes were higher in NLFS and COPD-CS (p < 0.05). Eosinophils were higher in COPD-ES and NLFS relative to NS (p < 0.05). ESR and CRP were elevated in NLFS and both COPD groups compared with NS (p < 0.05). In COPD, higher blood inflammatory cell counts were associated with poorer lung function (negative correlations; p < 0.05). Peripheral blood inflammatory markers are increased in smokers, including those with preserved lung function, and in COPD. Differences in eosinophil patterns between COPD current smokers and ex-smokers suggest inflammatory heterogeneity and should be confirmed in larger, well-characterized cohorts. These findings support the move towards careful personalized medicine interventions, based on individual inflammatory profiles. Cigarette smoking causes inflammation throughout the body and in the lungs, and it plays a key role in the development of chronic obstructive pulmonary diseases (COPD). In this study, we looked at signs of inflammation in the blood from smokers and people with COPD and compared them with those of people who have never smoked. We recruited 80 people, divided into four groups: non-smokers, smokers with normal lung function, current smokers with COPD, and ex-smokers with COPD. We measured different types of white blood cells and common blood markers of inflammation and compared these results with lung function test results. We found that smokers, even those with normal lung function, had higher levels of inflammation in their blood than non-smokers. People with COPD also had higher inflammatory markers, and higher blood inflammation was linked to worse lung function. Some differences were seen between current and ex-smokers with COPD, particularly in the level of eosinophils, suggesting that not all people with COPD have the same type of inflammation. Overall, the findings show that smoking is linked to increased inflammation in the blood, even before lung disease becomes obvious. The differences seen between individuals supports the need for more personalized approaches to COPD treatment, based on each person’s inflammatory profile.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: